Tandem Diabetes (TNDM) Tops Q4 EPS by 22c, Revenues Beat; Offers FY19 Revenue Guidance Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Tandem Diabetes Care Reports 2018 Financial Results and 2019 Financial Guidance
February 26, 2019 4:05 PM ESTSAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today reported its financial results for the quarter and year ended December 31, 2018 and financial guidance for the year ending December 31, 2019.
In comparing the fourth quarter of 2018 to the same period of 2017:
Pump shipments increased 133 percent to 16,168 pumps from 6,950 pumps Sales increased 89 percent to $76.2 million from $40.3 million Operating margin improved to 1 percent from negative 24 percentIn comparing the year ended December 31, 2018 to the same period of 2017:
... More